Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maeve Oconnor

Allergy & Immunology Charlotte, NC Medical Doctor

NPI 1114956752 CMS profile 50249

1523 Elizabeth Ave, Suite 200, Charlotte, NC 28204

Open in the dashboard

General payments

$2,162,106

2,873 records reported · program years 2019–2025

Research payments

$20,708

Paid to them · 21 records reported · program years 2019–2025

Ownership & investment interest

$4,000

2 holdings reported · through program year 2025

Research they led as principal investigator

$49,733 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Maeve Oconnor of Charlotte, NC is reported in the CMS Open Payments database as having received $2,162,106 across 2,873 general payments and $20,708 in research payments paid to them. Separately, studies naming them as principal investigator received $49,733 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $4,000 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $647,595 478
2024 General $462,144 430
2024 Research $7,250 1
2023 General $489,641 772
2022 General $231,246 434
2022 Research $3,712 7
2021 General $126,556 277
2021 Research $4,194 9
2020 General $104,608 201
2019 General $100,315 281
2019 Research $5,552 4
2025 Ownership $2,000 1
2024 Ownership $2,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maeve Oconnor
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Maeve Oconnor were reported at $647,595. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Maeve Oconnor Allergy & Immunology median Middle half National median
2019 $100,315 $594 $163–$1,512 $163
2020 $104,608 $426 $106–$1,233 $114
2021 $126,556 $638 $157–$1,708 $132
2022 $231,246 $790 $205–$1,961 $149
2023 $489,641 $852 $220–$2,147 $160
2024 $462,144 $865 $203–$2,267 $164
2025 $647,595 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $465,119 553 payments
  2. Consortium of Independent Immunology Clinics, LLC $309,141 6 payments
  3. Genzyme Corporation $263,206 208 payments
  4. Blueprint Medicines Corporation $179,200 167 payments
  5. AstraZeneca Pharmaceuticals LP $172,597 253 payments
  6. Pharming Healthcare, Inc. $162,854 237 payments
  7. Regeneron Healthcare Solutions, Inc. $97,917 159 payments
  8. OptiNose US, Inc. $84,686 273 payments
  9. ARS Pharmaceuticals Operations, Inc. $71,104 52 payments
  10. BioCryst US Sales Co., LLC $71,104 115 payments
  11. Other $285,178 850 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $942,004 328 payments
  2. Consulting Fee $629,209 118 payments
  3. Travel and Lodging $267,767 719 payments
  4. Honoraria $255,571 85 payments
  5. Food and Beverage $62,314 1,613 payments
  6. Education $5,224 8 payments
  7. Gift $17 2 payments
Products named General payments · program years 2019–2025
  1. NUCALA Immunology $380,165 439 payments
  2. DUPIXENT Immunology $213,054 193 payments
  3. RUCONEST $145,515 205 payments
  4. AYVAKIT $137,793 122 payments
  5. TEZSPIRE $107,808 116 payments
  6. Xhance $84,658 272 payments
  7. DUPIXENT Inflammation And Immunology $71,541 122 payments
  8. NEFFY $71,104 52 payments
  9. NUCALA Respiratory $54,203 66 payments
  10. Orladeyo $49,555 114 payments
  11. Other $339,769 1,023 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Consortium of Independent Immunology Clinics, LLC $7,250 1 payment
  2. Sanofi US Services Inc. $5,552 4 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $4,194 9 payments
  4. Teva Pharmaceuticals USA, Inc. $3,712 7 payments

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

203

Median for Allergy/ Immunology: 449

Drug cost

$652,248

Median for Allergy/ Immunology: $169,700

Branded share of claims

35.5%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Takhzyro Lanadelumab-Flyo Brand 13 $473,470
Xembify Immune Globulin,gamma(Igg)klhw Brand 18 $89,612
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 14 $82,160
Symbicort Budesonide/Formoterol Fumarate Brand 14 $4,113
Hydroxyzine Hcl Generic 15 $737
Cromolyn Sodium Generic 11 $726
Levocetirizine Dihydrochloride Generic 17 $662
Montelukast Sodium Generic 35 $362
Albuterol Sulfate Hfa Albuterol Sulfate Brand 13 $212
Famotidine Generic 29 $185

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$8,269

Medicare's payments for the services billed

Medicare patients

39

Average age 72

Services billed

500

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 51%
COPD 36%
Depression 31%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$57,941 — —
NUCALA
$53,198 — —
AYVAKIT
$47,407 — —
TEZSPIRE
$29,987 — —
RUCONEST
$26,945 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

2,894 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record